IOVA
Iovance Biotherapeutics Inc · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website iovance.com
- Employees(FY) 503
- ISIN US4622601007
Performance
-23.87%
1W
-14.09%
1M
+11.91%
3M
+132.73%
6M
+25.95%
YTD
+36.53%
1Y
Profile
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel that is in Phase II clinical trial for the treatment of metastatic melanoma and cervical cancer. It also develops LN-145 for the treatment of metastatic non-small cell lung cancer; IOV-4001 for the treatment of melanoma non-small cell lung cancer; IOV-2001; and IOV-3001. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; Novartis Pharma AG; Melanoma Institute Australia; and Beth-Israel Deaconess Medical Center. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
Investment Analysis Report: IOVA
Overview
In this investment analysis report, we will delve into the financial statements of IOVA, a company operating in the Health Technology sector within the Biotechnology industry. We will analyze the company's valuation, financial health, earnings and revenue growth, profitability, operating margin, operatin...
Technical Analysis of IOVA 2024-05-10
Overview:
In analyzing the technical indicators for IOVA over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potential inv...
Recent News & Updates
- 2024-05-17 17:15
- 2024-05-17 05:15
- 2024-05-16 09:30
4 Small-Cap Value Stocks That Could Go Parabolic(Motley Fool)
- 2024-05-13 14:25
- 2024-05-13 12:42
- 2024-05-11 10:00
The 3 Most Undervalued Biotech Stocks to Buy in May 2024(InvestorPlace)
- 2024-05-10 22:00
The 3 Most Undervalued Biotech Stocks to Buy in May 2024(Investorplace)
- 2024-05-10 14:03
Why Iovance Stock Is Down 18% Today(Motley Fool)
- 2024-05-10 13:35
- 2024-05-10 12:55
- 2024-05-10 12:33
- 2024-05-10 11:25
- 2024-05-10 10:58
- 2024-05-09 22:58
- 2024-05-09 16:27
Iovance Biotherapeutics: Q1 Earnings Snapshot(Associated Press Finance)
- 2024-05-09 16:23
- 2024-05-09 16:01
- 2024-05-09 08:57
- 2024-05-09 04:01
- 2024-05-06 10:40
- 2024-05-06 09:56
- 2024-05-05 21:56
- 2024-05-01 06:01
- 2024-04-30 18:01
- 2024-04-30 06:01
Iovance Biotherapeutics to Present at Upcoming Conferences(GlobeNewswire)
- 2024-04-29 18:01
Iovance Biotherapeutics to Present at Upcoming Conferences(Globenewswire)
- 2024-04-29 14:15
- 2024-04-28 14:44
- 2024-04-27 07:00
The Top 3 Biotech Stocks to Buy in April 2024(InvestorPlace)
- 2024-04-26 19:00
The Top 3 Biotech Stocks to Buy in April 2024(Investorplace)
Page 1 of 8
previousnext